Stock Ratings / Health Care / WGS / earnings

ADUS (69) PRVA (57) TDOC (56) AVAH (65) ⌘ Pro Terminal →

GeneDx Holdings Corp. (Class A) (WGS) Next Earnings Date & Expected ±12.5% Move

$71.02 +9.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $72.14

GeneDx Holdings Corp. (Class A) (WGS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.12B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $72.14 (+1.57%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WGS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY WGS SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)

Altman Z-Score 3.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (24% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$67.33-5.5% Next Q

Q2 (-2Q)

Grade C-$63.61-11.7% Next Q

Q3 (-1Q)

Grade C$56.15+26.5% Next Q

Current

Grade D+$71.02+0% Hist 90D α

Trajectory: C- (50) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WGS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, WGS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 67.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($79.04) or 200D SMA ($71.93) invalidates the momentum regime and cuts Target Base ($71.02) toward Bear Floor ($55.40).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WGS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WGS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$8.88 Expected Swing

MODEL EARNINGS SETUP GAUGE

WGS Quantitative Pre-Earnings Setup: 58/100

Trailing EPS: $4.25 • YoY Revenue Growth: 40%

Model Bullish Setup (58/100)Model Risk Weight (42/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$427.5M	-$21.0M	$14.3M	69.7%
FY 2024	2024-12-31	$305.4M	-$52.3M	-$34.0M	63.6%
FY 2023	2023-12-31	$202.6M	-$175.8M	-$180.1M	69.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WGS)

✓Walkthrough of WGS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WGS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.93%📐 HORIZONTAL RANGE

2026-10-30O $69.32H $71.02L $66.80C $71.02VOL 886.0K

RES: $124.0SUP: $54.77SMA50: $79.04SMA200: $71.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WGS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WGS Butterfly Map → + Track WGS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WGS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WGS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WGS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WGS)

Health Care Rank #224 of 1016 ⚔️ ADUS vs WGS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WGS vs. ADUS, PRVA, TDOC, AVAH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GeneDx Holdings Corp. (Class A) (WGS) ranks #224 by composite RQD confidence (58/100, grade D+) and #253 by equity capitalization ($2.12B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with WGS at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WGS ACTIVE GeneDx Holdings Corp. (Class A)	D+	58/100	—	69.7%	-4.1%	+9.79%	$2.12B	Benchmark Subject
ADUS Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-wgs →
PRVA Privia Health Group Inc.	D+	57/100	122.6x	—	10.5%	+0.71%	$2.81B	/prva-vs-wgs →
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-wgs →
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-wgs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818331

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GeneDx Holdings Corp. (Class A) (WGS) reported GAAP revenue of $427.5M (+40.0% vs. FY2024 revenue of $305.4M , and +111.1% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of $33.3M, and free cash flow of $14.3M (+142.0% YoY). On the balance sheet, WGS closed FY2025 with $523.7M in total assets against $48.2M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$427.5M	-$21.0M	$33.3M	$14.3M	$523.7M	$48.2M
FY2024 (FY)	2024-12-31	$305.4M	-$52.3M	-$28.5M	-$34.0M	$419.4M	$51.9M
FY2023 (FY)	2023-12-31	$202.6M	-$175.8M	-$180.1M	-$180.1M	—	—

3. WGS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, GeneDx Holdings Corp. (Class A) (NASDAQ: WGS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $71.02 (+9.79% 1D, market cap $2.12B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, WGS ranks #224 in composite RQD confidence.

How does WGS compare to ADUS and PRVA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), WGS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 69.7%, and ROIC of -4.1%. By comparison, ADUS (Addus HomeCare Corporation) holds a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B) and PRVA (Privia Health Group Inc.) posts a D+ grade (57/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.81B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WGS?

Per WGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818331), GeneDx Holdings Corp. (Class A) generated $427.5M in revenue (+40.0% YoY), -$21.0M in net income, and $14.3M in free cash flow against $523.7M in total assets and $48.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WGS trading relative to its 50-day, 200-day, and 52-week technical levels?

WGS last traded at $71.02 (+9.79% on volume of 921,832 shares), positioning the stock -10.15% below its 50-day simple moving average ($79.04) and -1.27% below its 200-day simple moving average ($71.93). Across its 52-week range of $32.21 to $170.87, WGS sits at the 28.0% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($62.14 to $79.90).

WGS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is WGS's next earnings date?

Based on SEC filing cadence, GeneDx Holdings Corp. (Class A) (WGS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is WGS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for WGS, spanning a range between $62.14 and $79.9.

Direct Sub-Reports: WGS RQD Cockpit WGS 12M Forecast WGS Earnings & Move WGS Dividends & DRIP WGS Insiders & 13F WGS Whale Options WGS Profit Sankey WGS News & Why